Peripheral applications of drug-coated balloons: past, present and future.
Drug-coated balloon (DCB) technologies represent the latest and hottest development in the field of endovascular treatment of peripheral arterial disease. Initial experience with paclitaxel-coated balloon use in the femoral artery has demonstrated lower mid-term restenosis and superior mid-term clinical outcomes in terms of improved wound healing and reduced repeat angioplasty rates compared with standard balloon angioplasty. Many companies are presently developing and/or improving DCB catheters and therefore ongoing, technical improvements of the already existing platforms, new drugs, and innovative carriers are expected. The ongoing basic research studies and various multicenter randomized, controlled trials that are currently in progress will offer valuable scientific insights regarding the long-term effectiveness and other crucial issues, such as efficacy in various vascular beds, optimal balloon dosage, and post angioplasty antiplatelet therapy. Future applications of these devices also could include in-stent restenosis, anastomotic stenosis of surgical bypass, and benign stenoses of the central venous system. The authors envision that DCB angioplasty will evolve to a major paradigm shift in the endovascular treatment of occlusive vascular diseases.
Department of Radiology, Guy's and St. Thomas' Hospitals, NHS Foundation Trust, 1st Floor Lambeth Wing, Lambeth Palace Road, London, SE1 7EH, UK. mkrokidis@hotmail.com
Miltiadis
M
Krokidis
Stavros
S
Spiliopoulos
Konstantinos
K
Katsanos
Tarun
T
Sabharwal
D000800:Angioplasty, Balloon / Q000295:instrumentation*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D020099:Coated Materials, Biocompatible; D054855:Drug-Eluting Stents; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use; D016491:Peripheral Vascular Diseases / Q000628:therapy*; D011474:Prosthesis Design; D016032:Randomized Controlled Trials as Topic
D020099:Coated Materials, Biocompatible; D017239:Paclitaxel